Ma 1999.

Methods	Study design: parallel‐group RCT Country: Korea Number randomized: Total: 80 Per group: brimonidine/brimonidine = 20; brimonidine/placebo = 20, placebo/brimonidine = 20, placebo/placebo = 20 Exclusions after randomization: none reported Number analyzed: Total: 80 Per group: brimonidine/brimonidine = 20; brimonidine/placebo = 20, placebo/brimonidine = 20, placebo/placebo = 20 Unit of analysis (participants vs eyes): participant (1 eye per participant) Losses to follow‐up: none reported How was missing data handled?: N/A Reported power calculation: no Unusual study design?: none
Participants	Age (mean ± SD; years): overall = 58.4 ± 8.9, brimonidine/brimonidine = 57.7, brimonidine/placebo = 58.0, placebo/brimonidine = 60.6, placebo/placebo = 57.5 Females: brimonidine/brimonidine = 35%, brimonidine/placebo = 55%, placebo/brimonidine = 55%, placebo/placebo = 45% Inclusion criteria: none listed Exclusion criteria: people who had glaucoma or intraocular surgery, who had already received any systemic alpha‐agonist or had a hypersensitivity to any alpha‐agonist Equivalence of baseline characteristics: yes, "No significant pretreatment differences in terms of age, sex, iris color, or baseline IOP were noted among treatment groups."
Interventions	Intervention 1: brimonidine 0.2%, 30 to 60 min before and immediately after 180° ALT Intervention 2: brimonidine 0.2%, 30 to 60 min before and placebo immediately after 180° ALT Intervention 3: placebo, 30 to 60 min before and brimonidine 0.2% immediately after 180° ALT Intervention 4: placebo, 30 to 60 min before and immediately after Length of follow‐up: Planned: 4 weeks Actual: 4 weeks
Outcomes	Primary outcome: IOP Secondary outcomes: IOP of the contralateral eye, mean heart rate, systolic BP Adverse events reported: yes Intervals at which outcomes assessed: 1, 2, 3 hours; 1 day; 1, 4 weeks
Notes	Trial registration: not reported Funding sources: "This study was supported by the Research Institute of Clinical Medicine, Chonnam University Hospital." Disclosures of interest: none reported Study period: not reported Reported subgroup analyses: no
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Randomization sequence not described.
Allocation concealment (selection bias)	Unclear risk	Allocation concealment not reported.
Masking of participants and personnel (performance bias)	Unclear risk	No information on masking of participants and personnel reported.
Masking of outcome assessment (detection bias)	Unclear risk	No information on efforts to mask the outcome assessors reported.
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Unclear whether there were any missing data or how they were handled.
Selective reporting (reporting bias)	Unclear risk	Unclear whether there was selective reporting.
Other bias	Low risk	None